Zyloric 300 Tablet contains Allopurinol 300mg, a xanthine oxidase inhibitor used primarily to manage hyperuricemia and prevent gout attacks. By inhibiting the enzyme xanthine oxidase, Allopurinol reduces the production of uric acid, thereby lowering serum urate levels and minimizing the risk of urate crystal deposition in joints and tissues. This medication is indicated for the treatment of chronic gout, prevention of uric acid nephropathy during cancer chemotherapy, and management of recurrent calcium oxalate calculi associated with hyperuricosuria. Zyloric 300 is also utilized in conditions characterized by elevated uric acid levels, such as Lesch-Nyhan syndrome and certain malignancies. The tablet should be administered orally, with dosage adjusted based on clinical response and renal function. Common adverse effects include rash, gastrointestinal disturbances, and hypersensitivity reactions; severe hypersensitivity syndrome, though rare, necessitates immediate discontinuation. Regular monitoring of renal function, liver enzymes, and serum uric acid levels is recommended during therapy. Caution is advised in patients with renal impairment and those on concomitant medications metabolized via xanthine oxidase. Zyloric 300 Tablet offers an effective therapeutic option for long-term urate control, improving patient outcomes in hyperuricemic conditions.